---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-025452"
form_type: "8-K"
ticker: "CSBR"
cik: "0000771856"
company_name: "CHAMPIONS ONCOLOGY, INC."
filed_at: "2023-07-24T23:59:59+00:00"
generated_at: "2026-06-13T04:37:19.130952+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Champions Oncology reports Q4 revenue $13.1M (+2% YoY); full-year record $53.9M but operating loss widens

## Summary
- Q4 operating loss of $2.5M vs $311K loss a year ago; includes $807K asset impairment on Lumin platform.
- Full-year operating loss $5.3M vs income $607M; adjusted EBITDA loss $1.3M vs +$3.1M.
- Gross margin fell to 44% (Q4) and 45% (FY) from 52% in prior-year periods due to study cancellations.
- Cash $10.1M, no debt; CFO projects return to profitability in H2 of current fiscal year.
- Announced formation of wholly owned biotech subsidiary Corellia AI for therapeutic drug discovery.

## SEC filing metadata
- accession: 0001628280-23-025452
- form_type: 8-K
- ticker: CSBR
- cik: 0000771856
- company_name: CHAMPIONS ONCOLOGY, INC.
- filed_at: 2023-07-24T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/771856/000162828023025452/0001628280-23-025452-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/771856/000162828023025452/csbr-20230724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-025452
- JSON: https://secwatch.observer/filing/0001628280-23-025452.json
- Plain text: https://secwatch.observer/filing/0001628280-23-025452.txt

## Key facts
- Earnings Releases
  CHAMPIONS ONCOLOGY, INC. reported fiscal year ended April 30, 2023 results: revenue $53.9 million.
  - Period: fiscal year ended April 30, 2023
  - Revenue: $53.9 million
  - Result: reported results
  source text: Total revenue for fiscal year 2023 was $53.9 million, an increase of 10%, compared to $49.1 million for fiscal year 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/771856/000162828023025452/0001628280-23-025452-index.htm
- Earnings Releases
  CHAMPIONS ONCOLOGY, INC. reported three months ended April 30, 2023 results: revenue $13.1 million.
  - Period: three months ended April 30, 2023
  - Revenue: $13.1 million
  - Result: reported results
  source text: Total revenue for the fourth quarter of fiscal 2023 was $13.1 million, an increase of 2%, compared to $12.9 million for the same period last year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/771856/000162828023025452/0001628280-23-025452-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.